Healthtech funding in H1 2022
European Healthtech startup funding raised during H1 2022.
In H1 2022, 325 European Healthtech companies closed 329 funding rounds and raised €4.1B in equity funding (excluding debt and grants), up 9.9% versus H1 2021. Debt rounds added €500M. France led by capital raised, and Bpifrance was the most active investor. Data as of 20 Nov 2026.
Equity funding
€4.1B
+9.9% vs H1 2021 · excl. debt & grants · +€500M debt
Funding rounds
329
+41.8% vs H1 2021
Companies
325
Top country
France
Rank among sectors
#5
7.1% of sector funding
Debt financing
€500M
10.9% of total
Top-10 round share
29.4%
of disclosed capital
Rounds ≥ €100M
3
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H1 2022 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €1.0B | 65 |
| Feb | €790M | 60 |
| Mar | €916M | 46 |
| Apr | €475M | 44 |
| May | €529M | 47 |
| Jun | €927M | 67 |
Top countries
by € raisedHealthtech — top countries by capital, H1 2022 — interactive chart.
Data table
| Healthtech — top countries by capital, H1 2022 | |
|---|---|
| France | €1.3B |
| UK | €1.0B |
| Germany | €479M |
| Switzerland | €462M |
| Netherlands | €392M |
| Spain | €188M |
| Sweden | €171M |
| Belgium | €131M |
Stage mix
by € raisedHealthtech — stage mix, H1 2022 — interactive chart.
Data table
| Healthtech — stage mix, H1 2022 | |
|---|---|
| Other | €1.5B |
| Series B | €1.1B |
| Series A | €899M |
| Debt | €500M |
| Series C | €249M |
| Seed | €206M |
| Series D+ | €80M |
| Grant | €17M |
| Pre-Seed | €9.8M |
| Crowdfunding | €2.5M |
Exits & M&A
28 Acquisition · 1 IPO29 exits · €7.7B disclosed.
| Pharma Intelligence | Acquisition | Feb 2022 | €2.3B |
| Norgine | Acquisition | Jun 2022 | €1.8B |
| Zogenix | Acquisition | Jan 2022 | €1.7B |
| SPT Labtech | Acquisition | Jun 2022 | €757M |
| ReViral | Acquisition | Apr 2022 | €483M |
| Normax | IPO | Jun 2022 | €300M |
Top deals
largest disclosed rounds in H1 2022| Company | Stage | Date | Amount |
|---|---|---|---|
| Doctolib | Debt | Mar 2022 | €500M |
| Patient21 | Other | Jan 2022 | €126M |
| Leyden Labs | Series B | Jan 2022 | €124M |
| Imcheck Therapeutics | Other | Jun 2022 | €96M |
| MindMaze | Other | Feb 2022 | €92M |
| OMass Therapeutics | Series B | Apr 2022 | €90M |
| Ori Biotech | Series B | Jan 2022 | €88M |
| Padoa | Other | Feb 2022 | €80M |
| Precirix | Series B | Mar 2022 | €80M |
| DistalMotion | Series D+ | Jan 2022 | €80M |
| Proximie | Series C | Jun 2022 | €77M |
| Ambagon Therapeutics | Series A | Jan 2022 | €75M |
| Owkin | Series B | Jun 2022 | €74M |
| Diabeloop | Other | Jun 2022 | €70M |
| Immunos Therapeutics | Series B | Jun 2022 | €68M |
Top investors
most active in H1 2022, by deal count- Bpifrance7 deals
- High-Tech Gründerfonds (HTGF)7 deals
- INKEF Capital6 deals
- Scottish Enterprise6 deals
- Octopus Ventures5 deals
- Omnes Capital5 deals
- Venture Kick5 deals
- Andera Partners4 deals
- Atlantic Labs4 deals
- BioMedPartners4 deals